Click here for more information about how Roche is responding to COVID-19
Questions About Roche Medicines? Visit medinfo.roche.com
Foundation Medicine® is a world-leading molecular insights company that is making precision medicine a reality for thousands.9
Our Services
Our comprehensive genomic profiling approach broadly analyses the tumour genome to identify clinically-relevant genomic alterations† and signatures and potentially expand patients’ treatment options.1,2,4–8,10–14
A comprehensive approach to genomic profiling
Our comprehensive genomic profiling approach analyses known cancer-relevant genes, Tumour Mutational Burden (TMB) or blood Tumour Mutational Burden (bTMB) and Microsatellite Instability (MSI) in a single test.‡1–8
Genomic insights that support clinical decision-making
A clear, in-depth report provides insights on a patient’s genomic profile as well as associated targeted therapies, immunotherapies and relevant clinical trials.15
A high-quality portfolio of services
Our extensively validated comprehensive genomic profiling services provide powerful insights to guide efficient, personalised treatment decisions at optimal times beneficial to your patients’ journeys.1–8
About Us
Through this collaboration, Roche is bringing Foundation Medicine's comprehensive genomic profiling services to cancer patients around the world. The Roche and Foundation Medicine collaboration combines Roche's expertise and commitment in oncology with Foundation Medicine's leading technology, validation and experience in cancer profiling.9
Ordering
To order a test, start by selecting your country of residence.
Need More Details?
We're committed to excellent service. If you have questions or need assistance, our client services team is available to help.
*Comprehensive genomic profiling is a next-generation sequencing approach, able to detect both novel and known variants, including all classes of genomic alterations (base substitutions, insertions and deletions, copy number alterations and rearrangements) and genomic signatures (for example Tumor Mutational Burden [TMB] or blood Tumour Mutational Burden [bTMB], Microsatellite Instability [MSI], and Loss of Heterozygosity [LoH]), to provide prognostic, diagnostic and predictive insights that inform treatment decisions for individual patients across all cancer types (CGP insights can be generated either from an end-to-end, curated reporting service or through in-house testing solutions).
†Base substitutions, insertions & deletions, copy number alterations and rearrangements.
‡TMB reported by FoundationOne CDx and FoundationOne Heme. bTMB reported by FoundationOne Liquid CDx. MSI reported by FoundationOne CDx and FoundationOne Heme, MSI-H reported by FoundationOne Liquid CDx.